Paul Peter Tak, Chief Executive Officer at Candel Therapeutics, Inc. (CADL), sold 51,944 shares at $8.77 ($456K) on 2025-03-18, disclosed to the SEC on 2025-03-20.
Scheduled sale ($456k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $8.77 | 25,772 | $226K | 49.6% |
| 2 | $8.77 | 25,772 | $226K | 49.6% |
| 3 | $9.00 | 400 | $4K | 0.8% |
| Total | $8.77 avg | 51,944 | $456K | 100% |
| Filing → |
| CADL | SELL | 2025-01-10 | $348K | — | Filing → |
| CADL | SELL | 2024-12-03 | $445K | — | Filing → |
| CADL | SELL | 2024-07-19 | $292K | — | Filing → |